ISDA

Deposition Date 2018-07-30

Release Date 2018-08-22

Last Version Date 2024-05-15

Entry Detail

PDB ID:

6H6Q

Keywords:

APOPTOSIS

Title:

Fragment Derived XIAP inhibitor

Biological Source:

Source Organism:

Homo sapiens (Taxon ID: 9606)

Host Organism:

Escherichia coli BL21(DE3)

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.63 Å

R-Value Free:

0.27

R-Value Work:

0.25

R-Value Observed:

0.25

Space Group:

P 41 21 2

Download Validation Report

Macromolecular Entities

Protein Blast

Polymer Type:polypeptide(L)
Molecule:E3 ubiquitin-protein ligase XIAP
Gene (Uniprot):XIAP
Chain IDs:A, B
Chain Length:127
Number of Molecules:2
Biological Source:Homo sapiens

UniProt ID:P98170 Pfam ID:PF00653

Ligand Molecules

FUK

Primary Citation

A Fragment-Derived Clinical Candidate for Antagonism of X-Linked and Cellular Inhibitor of Apoptosis Proteins: 1-(6-[(4-Fluorophenyl)methyl]-5-(hydroxymethyl)-3,3-dimethyl-1 H,2 H,3 H-pyrrolo[3,2- b]pyridin-1-yl)-2-[(2 R,5 R)-5-methyl-2-([(3R)-3-methylmorpholin-4-yl]methyl)piperazin-1-yl]ethan-1-one (ASTX660).

Johnson, C.N, Ahn, J.S, Buck, I.M, Chiarparin, E, Day, J.E.H, Hopkins, A, Howard, S, Lewis, E.J, Martins, V, Millemaggi, A, Munck, J.M, Page, L.W, Peakman, T, Reader, M, Rich, S.J, Saxty, G, Smyth, T, Thompson, N.T, Ward, G.A, Williams, P.A, Wilsher, N.E, Chessari, G.Show

J. Med. Chem. 61 7314 7329 (2018)

PMID: 30091600 DOI: 10.1021/acs.jmedchem.8b00900

Abstact

Inhibitor of apoptosis proteins (IAPs) are promising anticancer targets, given their roles in the evasion of apoptosis. Several peptidomimetic IAP antagonists, with inherent selectivity for cellular IAP (cIAP) over X-linked IAP (XIAP), have been tested in the clinic. A fragment screening approach followed by structure-based optimization has previously been reported that resulted in a low-nanomolar cIAP1 and XIAP antagonist lead molecule with a more balanced cIAP-XIAP profile. We now report the further structure-guided optimization of the lead, with a view to improving the metabolic stability and cardiac safety profile, to give the nonpeptidomimetic antagonist clinical candidate 27 (ASTX660), currently being tested in a phase 1/2 clinical trial (NCT02503423).

Legend

Protein

Chemical

Disease

Primary Citation of related structures